Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1 - 1,000 - Monthly Reach
Unique listeners across all episodes (30 days)
1 - 5,000 - Active Followers
Loyal subscribers who consistently listen
1 - 500
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Minimal Effective Dose: The Key to Preventing Muscle Loss on GLP-1s
Apr 28, 2026
Unknown duration
GLP-1 Drugs... Are They Destroying Muscle? — What Semaglutide, Tirzepatide & Retatrutide Data Actually Shows
Apr 22, 2026
Unknown duration
The Peptide Ban Is Ending: FDA Officially Begins Reclassification Process for BPC-157, TB-500 & More
Apr 16, 2026
Unknown duration
Grey Market Peptides – Safety, Testing, and What You Need to Know
Apr 15, 2026
Unknown duration
GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing
Apr 9, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | |
|---|---|---|---|---|
| 4/28/26 |  Minimal Effective Dose: The Key to Preventing Muscle Loss on GLP-1s | Using the minimal effective dose of GLP-1 medications may be the key to preserving muscle during weight loss. This episode explains how to implement it alongside nutrition and training. | — | |
| 4/22/26 |  GLP-1 Drugs... Are They Destroying Muscle? — What Semaglutide, Tirzepatide & Retatrutide Data Actually Shows | A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat. This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology — bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway — is trying to solve the problem. For clinicians, patients, and anyone paying attention to where obesity medicine is actually going.This podcast is for informational purposes only and is not medical advice. | — | |
| 4/16/26 |  The Peptide Ban Is Ending: FDA Officially Begins Reclassification Process for BPC-157, TB-500 & More | Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice and scheduling a July 2026 Pharmacy Compounding Advisory Committee meeting. This episode breaks down the full regulatory timeline, what the Category 1 vs Category 2 framework means, what today's action specifically does, and what patients and clinicians should know right now. Clinical, evidence-grounded, no hype. | — | |
| 4/15/26 |  Grey Market Peptides – Safety, Testing, and What You Need to Know | A clinical breakdown of grey market peptide safety, including contamination risks, testing standards, and how peptide quality impacts biological effects. | — | |
| 4/9/26 |  GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing | GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing | — | |
| 4/2/26 |  BPC-157 Deep Dive: Healing Mechanism, Dosing, TB-500 Stack & Why It’s BANNED in Sports | A clinical deep dive into BPC-157 covering mechanism, recovery science, dosing patterns, TB-500 synergy, and why it is banned in professional sports. | — | |
| 3/23/26 |  MOTS-C: The Mitochondrial Peptide for Metabolism and Insulin Sensitivity | MOTS-C is one of the most unique peptides being studied today — not because of what it does, but because of where it comes from.Unlike most peptides, MOTS-C is encoded inside your mitochondria, the part of the cell responsible for energy production. That makes it part of a growing category of mitochondrial signaling peptides that may play a role in metabolism, aging, and cellular energy regulation.In this episode of Peptides Explained, we break down:• What MOTS-C is and how it’s produced• How it activates AMPK, the body’s metabolic “master switch”• Why it’s being studied as a potential exercise mimetic• Its effects on insulin sensitivity and glucose metabolism• What the animal research shows vs. the current state of human data• Where it may fit in the broader peptide landscape• Risks, limitations, and why it remains experimentalThis episode focuses on the biology and clinical context behind MOTS-C — not the hype.Disclaimer: This podcast is for informational purposes only and is not medical advice. MOTS-C is not FDA-approved and is currently considered an investigational peptide. Always consult a licensed healthcare professional before considering any therapy.Peptide science is evolving — and understanding the mechanism is the first step. | — | |
| 3/14/26 |  Do Growth Hormone Peptides Actually Work? CJC-1295, Ipamorelin & Sermorelin Explained | Growth hormone peptides are some of the most talked-about compounds in longevity medicine, metabolic health, and hormone optimization. But how do they actually work inside the body?In this episode of Peptides Explained, we break down the science behind four growth hormone secretagogues: Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin.Instead of injecting growth hormone directly, these peptides stimulate the pituitary gland to release the body’s own growth hormone through different biological pathways.We explore the physiology of the growth hormone axis, the role of GHRH, IGF-1, and ghrelin signaling, and how these peptides may influence metabolism, recovery, and sleep.You’ll also learn the differences between these compounds, why CJC-1295 and Ipamorelin are often stacked, and what the clinical research actually shows.Topics covered in this episode include:• How growth hormone is regulated in the body• The biological role of ghrelin and GH pulses during sleep• The difference between Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin• What DAC (Drug Affinity Complex) means in CJC-1295• Potential effects on IGF-1, metabolism, and recovery• Possible side effects, including effects on prolactin and glucose metabolism• What the clinical evidence actually supportsAs always, this podcast focuses on biological mechanisms and scientific evidence so you can understand how peptide therapies interact with human physiology.Disclaimer:This episode is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before considering any therapy.If you'd like, I can also give you a very effective pinned comment for the YouTube video. That small detail often increases engagement and pushes the algorithm to recommend the episode more. | — |
Showing 8 of 8
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.